

PORTUGAL

Recent and planned changes in pharmaceutical pricing and reimbursement and overview of the medical devices system

P H A R M A C E U T I C A L S	<h3>Changes in pricing</h3> <ul style="list-style-type: none"> • Annual price review: non-generics; and hospital medicines not previously assessed and with sales above 1M€ (01/2014) • Margin changes: new values for fixed and percentage wholesale and pharmacy margins, which vary by price ranges (04/2014) • Discounts / rebates: end of the 6% deduction on the maximum price approved for reimbursed medicines (03/2013) • International reference pricing: countries changed from Spain, France and Slovakia to Spain, France and Slovenia (01/2014) • Generic prices: initial price of generics ceased to be calculated based on the internal reference price when there is an homogenous group (04/2014) 	<h3>Changes in reimbursement</h3> <ul style="list-style-type: none"> • Changes/modifications of reimbursement lists: delist of some pharmacotherapeutic groups and inclusion of new reimbursable groups (03/2014) • Changes/modifications in the reference price system (methodology): new homogeneous groups can be created monthly as a result of the introduction of new generics in the market (11/2013) • Reimbursement reviews: update of the criteria for the reimbursement assessment and review; introduction of the review of reimbursement whenever there's a change in the therapeutic indications (04/2014) • Other changes/modifications of the reimbursement system: for generics it is established a price threshold not lower than 20% of the medicine of reference price (04/2014)
	<h3>Other changes related to medicines</h3> <ul style="list-style-type: none"> • Establishment of National Pharmacy Therapeutic Committee, responsible for developing the National Medicines Formulary (hospitals and ambulatory)(02/2013) • Under implementation the SiNATS - National System for Health Technology Assessment, which will include a new Committee for HTA assessment 	
M E D I C E S	<h3>Pricing and reimbursement system of medical devices</h3> <ul style="list-style-type: none"> • Competent authority: Overall competence regarding health technology assessment and coding system lies with INFARMED, I.P., which is also responsible for the registration of medical devices commercialized in Portugal. • Price regulation: Pricing of medical devices is statutorily not regulated and can be freely set by the manufactures, except for certain classes of medical devices such as pacemakers, coronary stents and CDIs that have a maximum selling price to the NHS. • Reimbursement: A new Committee for HTA it's under implementation, which will be responsible for the assessment not only of pharmaceuticals, but also of medical devices. • Price sources/prices known: Prices for medical devices coded under the national coding scheme are retrospectively known through public hospital information feedback. 	